Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Centogene NV's 1-Year ROIIC % for the quarter that ended in Dec. 2023 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Centogene NV's 1-Year ROIIC % or its related term are showing as below:
CNTGF's 1-Year ROIIC % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 3.17 * Ranked among companies with meaningful 1-Year ROIIC % only.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Centogene NV 1-Year ROIIC % Related Terms
Centogene NV 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Centogene NV's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNTGF vs ISPC, CHEK, FUNI: 1-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Centogene NV's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Centogene NV 1-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Centogene NV's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Centogene NV's 1-Year ROIIC % falls into.
Centogene NV's 1-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -39.281 (Dec. 2023) - -38.683 (Dec. 2022) )
/
( 77.194 (Dec. 2023) - 57.625 (Dec. 2022) )
=
-0.598
/
19.569
=
-3.06%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Centogene NV (CNTGF) has a 1-Year ROIIC % of 0.00 as of Dec. 2023. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Centogene NV and its competitors.
Is Centogene NV's 1-Year ROIIC % too high?
Centogene NV's current 1-Year ROIIC % is 0.00. Overall, Centogene NV has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Centogene NV's 1-Year ROIIC % compare to ISPC and CHEK?
Centogene NV's 1-Year ROIIC % of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. The industry median 1-Year ROIIC % is 3.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Medical Diagnostics & Research company?
The median 1-Year ROIIC % among Medical Diagnostics & Research companies is 3.17, based on 206 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Centogene NV and its competitors. For the Medical Diagnostics & Research industry, the median 1-Year ROIIC % is 3.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Centogene NV's current 1-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centogene NV stock overvalued right now?
Centogene NV (CNTGF) has a current 1-Year ROIIC % of 0.00. The current 1-Year ROIIC % is 0.00. Centogene NV's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Centogene NV (CNTGF), the current 1-Year ROIIC % is 0.00 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Centogene NV is a United States-based company engaged in data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. The company operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its diagnostics segment provides targeted genetic sequencing and diagnostics services to patients. Its geographic regions are Europe, the Middle East, North America, and Latin America.
12GF Score
Get the complete analysis for CNTGF
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTGF has been successfully added to your 
